Get the app
US › Healthcare

AptarGroup Inc (ATR)

US · Healthcare · Medical Instruments & Supplies

$142.50-1.07%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$1.02B
Revenue YoY
+6.0%
Net profit
$32.6M
Profit YoY
-74.5%
EPS
$1.52
EPS estimate
$1.46
Net margin
3.2%

EPS came in at 1.52 against a street estimate of 1.46 — a beat of 4.1%.

Key statistics

Market cap
$8.31B
P/E
23.6
Forward P/E
21.0
P/B
3.08
Book value
$41.33
EPS (TTM)
$5.54
Dividend yield
1.49%
52-week high
$145.82
52-week low
$107.07
50-day MA
$125.78
200-day MA
$126.89
Beta
0.34

Analyst view

Analysts rate AptarGroup Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $162.25.

From the latest earnings call · 2026-10-30

MIXED Aptar delivered solid sales growth and beat EPS estimates, but margins declined, Beauty remains challenged, and emergency-medicine destocking still weighs on Pharma. Q3 FY26 Management specifically highlighted North American Beauty margin challenges, expanded Pharma operations in Mumbai, and cited customer launches in China. Analysts focused on emergency-medicine destocking, Pharma margins and pipeline conversion. Management said destocking should end in Q4 while productivity and broad-based demand support recovery. 2026-10-30…

Full summary in the app.

Shareholding

Insiders
0.86%
Institutions
97.90%

Largest institutional holders

FundStake
BlackRock Inc9.65%
State Farm Mutual Automobile Ins Co7.46%
Vanguard Portfolio Management, LLC5.72%
Morgan Stanley - Brokerage Accounts5.54%
Vanguard Capital Management, LLC4.55%
State Street Corp4.50%
Victory Capital Management Inc.4.02%
Geode Capital Management, LLC2.75%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Third-quarter 2026 net sales were $1,019,119, up from $961,131 in the third quarter of 2025. • Nine-month 2026 net sales were $3,
2026-10-30
Results announced · Q4 2026
HEADLINE NUMBERS • Third-quarter 2026 reported sales increased 6% to $1.02 billion from $961 million; core sales increased 5%. • Reported net income
2026-10-29
Reg FD disclosure · Q3 2026
APTARGROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Russian subsidiary Aptar Vladimir placed under temporary external administration by Russian F
2026-09-21
Board / officer change · Q3 2026
APTARGROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial numbers disclosed - This is a personnel/governance filing, not an earnings repor
2026-09-10
Board / officer change · Q3 2026
APTARGROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 10 to 11 directors on August 29, 2026 • New director appointment ef
2026-09-01
Quarterly report · Q2 2026
APTARGROUP, INC. - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Sales (6 months): $2,009,376 thousand, up 8.4% vs. $1,8
2026-07-31
Results announced · Q3 2026
APTAR GROUP, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Sales: $1.03 billion, up 6% reported / up 1% core sales (excluding currency
2026-07-30
Board / officer change · Q2 2026
APTARGROUP, INC. - FORM 8-K SUMMARY Filing Date: May 10, 2026 --- HEADLINE NUMBERS • Sign-on bonus for new Chief Accounting Officer: $105,000 (paya
2026-05-13

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.50 / share
ex-date Nov 12, 2026 · pay Dec 3, 2026
2026-11-12
Dividend$0.48 / share
ex-date Jul 30, 2026 · pay Aug 20, 2026
2026-07-30
Dividend$0.48 / share
ex-date May 6, 2026 · pay May 27, 2026
2026-05-06
Dividend$0.48 / share
ex-date Feb 4, 2026 · pay Feb 25, 2026
2026-02-04
Dividend$0.48 / share
ex-date Oct 23, 2025 · pay Nov 13, 2025
2025-10-23

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AptarGroup Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.